
The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.
Roy M. Fleischmann, MD, clinical professor of medicine at the University of Texas Southwestern Medical Center, assess a case of a 53-year-old woman with rheumatoid arthritis.
Case: Rheumatoid arthritis (RA) active disease in an adult female patient with inadequate response to methotrexate.
Initial Presentation and Treatment:
Subsequent Treatment and Follow-up:


